Fujian Green Pine Co Ltd

Fujian Green Pine maintains a capital structure with a debt-to-equity ratio of 0.15, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 2.83, suggesting it can cover short-term obligations but may face constraints in extreme scenarios. The price-to-book ratio of 2.9 and price-to-tangible-book ratio of 2.9 imply that the market values the company at a premium to its book value, potentially reflecting intangible assets or growth expectations. Profitability metrics show a return on equity (ROE) of 10.56% and a return on assets (ROA) of 6.89%, both below the industry median for Personal Products firms. The gross margin of 20.4% (calculated from gross profit of 452.6 million CNY on revenue of 2.22 billion CNY) is in line with industry norms, but the operating margin of 8.1% (180.6 million CNY) and net margin of 6.9% (153.2 million CNY) suggest moderate efficiency in converting revenue to profit. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation increases exposure to regional economic shifts and regulatory changes. No material geographic breakdown is available in the latest financials, limiting visibility into regional performance. Outlook data indicates a projected revenue growth of 5.2% for the current fiscal year and 3.8% for the next, driven by stable demand in the personal care market. However, the company's capital expenditure of -52.9 million CNY (negative due to cash inflow from asset disposals) suggests a focus on cost optimization rather than expansion. Risk factors include a net cash position that is negative after subtracting total debt, signaling potential liquidity constraints. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted metrics (516.6 million shares in both cases). No recent equity issuance or ATM/shelf registration activity has been disclosed to date. Recent filings and transcripts are not available in the current dataset, limiting insight into management commentary or strategic shifts. Analysts maintain a cautiously optimistic stance, with a mean recommendation of 1.67 (strong buy to buy) and a mean price target of 10.57 CNY, implying a 30% upside from the current market price of 8.16 CNY.